p53 is not related to Ki-67 immunostaining in the epithelial and mesenchymal components of female genital tract carcinosarcomas

Bałon,Beata; Kaznowska,Ewa; Ignatov,Atanas; Steć,Anna; Semczuk-Sikora,Anna; Schneider-Stock,Regine; Jóźwik,Maciej; Sulkowski,Stanisław; Cybulski,Marek; Szumiło,Justyna; Semczuk,Andrzej

doi:10.3892/or.2013.2615

p53 is not related to Ki-67 immunostaining in the epithelial and mesenchymal components of female genital tract carcinosarcomas

Authors:
- Beata Bałon
- Ewa Kaznowska
- Atanas Ignatov
- Anna Steć
- Anna Semczuk-Sikora
- Regine Schneider-Stock
- Maciej Jóźwik
- Stanisław Sulkowski
- Marek Cybulski
- Justyna Szumiło
- Andrzej Semczuk
View Affiliations

Affiliations: Municipal Hospital, Sanok, Poland, Oncology Hospital, Brzozów, Poland, Department of Obstetrics and Gynecology, Otto von Guericke University, Magdeburg, Germany, Department of Nephrology, Lublin Medical University, Lublin, Poland, Department of Obstetrics and Pathology of Pregnancy, Lublin Medical University, Lublin, Poland, Department of Pathology, Nurnberg‑Erlangen University, Erlangen, Germany, Department of Gynecology and Gynecologic Oncology, Medical University of Białystok, Białystok, Poland, Department of General Pathomorphology, Medical University of Białystok, Białystok, Poland, Department of Biochemistry and Molecular Biology, Lublin Medical University, Lublin, Poland, Department of Pathology, Lublin Medical University, Lublin, Poland, 2nd Department of Gynecology, Lublin Medical University, Lublin, Poland
Published online on: July 11, 2013 https://doi.org/10.3892/or.2013.2615
Pages: 1661-1668

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carcinosarcomas (CSs) are composed of two separate histological components and are rare neoplasms of the female genital tract. Therefore, CS pathogenesis has not yet been fully elucidated. In the present study, immunohistochemical techniques were used to determine the role of p53 and Ki-67 overexpression in female genital tract CSs. The study group was comprised of 36 patients with CSs originating from the uterus (n=31), cervix (n=3) and ovary (n=2), as well as 3 metastatic tissues. p53 was overexpressed in the epithelial component of 23 out of 36 (64%) tumors, and in the mesenchymal component of 20 out of 36 (56%) tumors. In both CS components, there was a significant correlation between p53 overexpression and patient age and ovarian metastases. Ki-67 overexpression was detected in the epithelial component in 15 out of 36 (42%) cases, and in the mesenchymal component in 13 out of 36 (36%) neoplasms. There was a significant correlation of p53 overexpression between the carcinomatous and sarcomatous components (R=0.884, P<0.001). A significant correlation was also found in Ki-67 immunoreactivity between the two CS components (R=0.676, P<0.001). However, p53 overexpression was not correlated with Ki-67 immunostaining in both tumor components. In conclusion, based on immunohistochemical results, p53 was overexpressed in more than half of the female genital tract CSs included in the present study, either at the epithelial or mesenchymal component. The correlation between p53 or Ki-67 overexpression in both tumor components supports the combination theory of histogenesis in the majority of these tumors.

View Figures

View References

1	FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 104:1792009. View Article : Google Scholar
2	McCluggage WG: Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 12:687–690. 2002. View Article : Google Scholar : PubMed/NCBI
3	Arend R, Doneza JA and Wright J: Uterine carcinosarcoma. Curr Opin Oncol. 23:531–536. 2011.PubMed/NCBI
4	Serkies K and Jassem J: Uterine carcinosarcoma. Ginekol Pol. 83:609–612. 2012.(In Polish).
5	D’Angelo E and Prat J: Uterine sarcomas: a review. Gynecol Oncol. 116:131–139. 2010.
6	McCluggage WG: Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol. 55:321–325. 2002. View Article : Google Scholar : PubMed/NCBI
7	Zaloudek C and Hendrickson MR: Mesenchymal tumors of the uterus. Blaustein’s Pathology of the Female Genital Tract. Kurman RJ: 5th edition. Springer; New York: pp. 561–615. 2002
8	Lopez-Garcia MA and Palacios J: Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol. 27:274–286. 2010. View Article : Google Scholar : PubMed/NCBI
9	Abeln ECA, Smit VT, Wessels JW, de Leeuw WJ, Cornelisse CJ and Fleuren GJ: Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol. 183:424–431. 1997. View Article : Google Scholar : PubMed/NCBI
10	Wada H, Enomoto T, Fujita M, et al: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 57:5379–5385. 1997.PubMed/NCBI
11	Jin Z, Ogata S, Tamura G, et al: Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol. 22:368–373. 2003. View Article : Google Scholar : PubMed/NCBI
12	Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J and Bast RC Jr: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol. 170:246–252. 1994. View Article : Google Scholar : PubMed/NCBI
13	Costa MJ, Vogelsan J and Young LJ: p53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. Mod Pathol. 7:619–627. 1994.
14	Liu FS, Kohler MF, Marks JR, Bast RC Jr, Boyd J and Berchuck A: Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol. 83:118–124. 1994.PubMed/NCBI
15	Soong R, Knowles S, Hammond IG, Michael C and Iacopetta BJ: p53 protein overexpression and gene mutation in mixed Mullerian tumors of the uterus. Cancer Detect Prev. 23:8–12. 1999. View Article : Google Scholar : PubMed/NCBI
16	Watanabe M, Shimizu K, Kato H, et al: Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. Gynecol Oncol. 82:563–567. 2001. View Article : Google Scholar : PubMed/NCBI
17	Semczuk A, Marzec B, Skomra D, et al: Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas. Oncology. 69:317–325. 2005.
18	de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM and Hollema H: Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol. 24:1368–1379. 2011.PubMed/NCBI
19	Yemelyanova A, Vang R, Kshirsagar M, et al: Immunohistochemical staining pattern of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 24:1248–1253. 2011. View Article : Google Scholar : PubMed/NCBI
20	Blom R, Guerrieri C, Stâl O, Malmström H, Sullivan S and Simonsen E: Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases. Gynecol Oncol. 68:18–24. 1998.
21	Lee SJ, Kim HS, Kim HS, Chun YK, Hong SR and Lee JH: Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas. Hum Pathol. 38:1226–1231. 2007. View Article : Google Scholar : PubMed/NCBI
22	Semczuk A, Skomra D, Chyzynska M, Szewczuk W, Olcha P and Korobowicz E: Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report. Pathol Res Pract. 204:203–207. 2008. View Article : Google Scholar : PubMed/NCBI
23	Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG and Wilkinson EJ: Histological Typing of Female Genital Tract Tumours. Springer-Verlag; Berlin, Heidelberg: 1994, View Article : Google Scholar
24	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
25	Prat J: FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 104:177–178. 2009. View Article : Google Scholar : PubMed/NCBI
26	FIGO. Changes in gynecologic staging by the International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 162:610–611. 1990.
27	Semczuk A, Skomra D, Cybulski M and Jakowicki JA: Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem J. 33:193–200. 2001. View Article : Google Scholar
28	Olcha P, Cybulski M, Skomra D, et al: The pattern of p14^ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations. Int J Gynecol Cancer. 20:993–999. 2010.
29	Alkushi A, Lim P, Coldman A, Huntsman D, Miller D and Gilks CB: Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol. 23:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
30	Iwasa Y, Haga H, Konishi I, et al: Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer. 82:512–519. 1998. View Article : Google Scholar : PubMed/NCBI
31	Bodner-Adler B, Bodner K, Obermair A, et al: Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res. 21:3069–3074. 2001.PubMed/NCBI
32	Amant F, Cadron I, Fuso L, et al: Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol. 98:274–280. 2005. View Article : Google Scholar : PubMed/NCBI
33	Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P and Finkelstein SD: Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol. 29:82–87. 1998. View Article : Google Scholar
34	Kanthan R, Senger J-LB and Diudea D: Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins. World J Surg Oncol. 8:602010. View Article : Google Scholar
35	Mayall F, Rutty K, Campbell F and Goddard H: p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology. 24:211–214. 1994. View Article : Google Scholar : PubMed/NCBI
36	Swisher EM, Gown AM, Skelly M, et al: The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol. 60:81–88. 1996.PubMed/NCBI
37	Sherman ME, Bur ME and Kurman RJ: p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 26:1268–1274. 1995. View Article : Google Scholar : PubMed/NCBI
38	Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P and Olivier M: TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 26:2157–2165. 2007. View Article : Google Scholar
39	Fujii H, Yoshida M, Gong ZX, et al: Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 60:114–120. 2000.PubMed/NCBI
40	Szukala SA, Marks JR, Burchette JL, Elbendary AA and Krigman HR: Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases. Int J Gynecol Cancer. 9:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
41	Taylor NP, Zighelboim I, Huettner PC, et al: DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol. 19:1333–1338. 2006.PubMed/NCBI
42	Yuan Y, Kim WH, Han HS, et al: Establishment and characterization of cell lines derived from uterine malignant mixed Müllerian tumor. Gynecol Oncol. 66:464–474. 1997.PubMed/NCBI
43	Hoon DS, Kitago M, Kim J, et al: Molecular mechanisms of metastasis. Cancer Metastasis Rev. 25:203–220. 2006. View Article : Google Scholar
44	Sreenan JJ and Hart WR: Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol. 19:666–674. 1995. View Article : Google Scholar
45	Jeczen R, Skomra D, Cybulski M, et al: P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin Exp Metastasis. 24:503–511. 2007. View Article : Google Scholar : PubMed/NCBI
46	Semczuk A, Schneider-Stock R and Szewczuk W: Prevalence of allelic loss at TP53 in endometrial carcinomas. Oncology. 78:220–228. 2010. View Article : Google Scholar
47	Nicòtina PA, Ferlazzo G and Vincelli AM: Proliferation indices and p53-immunocytochemistry in uterine mixed mullerian tumors. Histol Histopathol. 12:967–972. 1997.PubMed/NCBI
48	Abargel A, Avinoach I, Kravtsov V, Boaz M, Glezerman M and Menczer J: Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int J Gynecol Cancer. 14:354–359. 2004. View Article : Google Scholar : PubMed/NCBI
49	Buza N and Tavassoli FA: Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. Int J Gynecol Pathol. 28:514–521. 2009. View Article : Google Scholar : PubMed/NCBI
50	Koivisto-Korander R, Butzow R, Koivisto AM and Leminen A: Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumour Biol. 32:451–459. 2011. View Article : Google Scholar